A Randomised Open-label Phase II Trial of Consolidation with Nivolumab and Ipilimumab in Limited-stage SCLC After Chemo-radiotherapy
Latest Information Update: 07 Feb 2023
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Carboplatin; Cisplatin; Etoposide
- Indications Carcinoma; Small cell lung cancer
- Focus Therapeutic Use
- Acronyms STIMULI
- 31 Mar 2022 This trial has been completed in France, according to European Clinical Trials Database record.
- 28 Oct 2021 Planned End Date changed from 1 Jun 2022 to 1 Feb 2022.
- 28 Oct 2021 Status changed from discontinued to active, no longer recruiting.